blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3947379

EP3947379 - COMBINATIONS USEFUL IN A METHOD FOR TREATING SARCOMA [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  07.01.2022
Database last updated on 02.07.2024
FormerThe international publication has been made
Status updated on  02.10.2020
Most recent event   Tooltip20.03.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
PTC Therapeutics, Inc.
100 Corporate Court
South Plainfield, NJ 07080 / US
[2022/06]
Inventor(s)01 / WEETALL, Marla, L.
70 Burnham Parkway
Morristown, NJ 07960 / US
02 / CAO, Liangxian
17 Winesap Drive
East Brunswick, NJ 08816 / US
03 / SHEEDY, Josephine
114 Andrews Drive
Bordentown, NJ 08505 / US
04 / SPIEGEL, Robert
400 Elm Street
Westfield, NJ 08090 / US
[N/P]
Former [2022/06]01 / WEETALL, Marla, L.
Morristown, NJ 07960 / US
02 / CAO, Liangxian
East Brunswick, NJ 08816 / US
03 / SHEEDY, Josephine
Bordentown, NJ 08505 / US
04 / SPIEGEL, Robert
Westfield, NJ 08090 / US
Representative(s)V.O.
P.O. Box 87930
2508 DH Den Haag / NL
[2022/06]
Application number, filing date20776386.327.03.2020
[2022/06]
WO2020US25532
Priority number, dateUS201962825017P27.03.2019         Original published format: US 201962825017 P
[2022/06]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020198705
Date:01.10.2020
Language:EN
[2020/40]
Type: A1 Application with search report 
No.:EP3947379
Date:09.02.2022
Language:EN
The application published by WIPO in one of the EPO official languages on 01.10.2020 takes the place of the publication of the European patent application.
[2022/06]
Search report(s)International search report - published on:US01.10.2020
(Supplementary) European search report - dispatched on:EP22.11.2022
ClassificationIPC:C07D471/04, C07D403/04, C07D487/04, A61P35/00, A61K31/475, A61K31/337, A61K31/506, A61K31/655, A61K31/704, A61K45/06
[2022/51]
CPC:
A61K31/506 (EP,IL,US); A61K31/337 (EP,IL); A61K31/475 (EP,IL);
A61K31/655 (EP,IL); A61K31/704 (EP,IL); A61K45/06 (EP,IL,US);
A61P35/00 (EP,US); A61K2300/00 (IL) (-)
C-Set:
A61K31/337, A61K2300/00 (EP);
A61K31/475, A61K2300/00 (EP);
A61K31/506, A61K2300/00 (EP);
A61K31/655, A61K2300/00 (EP);
A61K31/704, A61K2300/00 (EP)
(-)
Former IPC [2022/06]C07D471/04, C07D403/04, C07D487/04
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/06]
TitleGerman:KOMBINATIONEN ZUR VERWENDUNG IN EINEM VERFAHREN ZUR BEHANDLUNG VON SARKOM[2022/06]
English:COMBINATIONS USEFUL IN A METHOD FOR TREATING SARCOMA[2022/06]
French:COMBINAISONS UTILES DANS UN PROCÉDÉ DE TRAITEMENT DU SARCOME[2022/06]
Entry into regional phase19.10.2021National basic fee paid 
19.10.2021Search fee paid 
19.10.2021Designation fee(s) paid 
19.10.2021Examination fee paid 
Examination procedure19.10.2021Examination requested  [2022/06]
11.07.2023Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
20.07.2023Amendment by applicant (claims and/or description)
Request for further processing for:The application is deemed to be withdrawn due to failure to indicate the wish to proceed further with the application
20.07.2023Request for further processing filed
20.07.2023Full payment received (date of receipt of payment)
Request granted
28.07.2023Decision despatched
The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
20.07.2023Request for further processing filed
20.07.2023Full payment received (date of receipt of payment)
Request granted
28.07.2023Decision despatched
Fees paidRenewal fee
23.03.2022Renewal fee patent year 03
21.03.2023Renewal fee patent year 04
20.03.2024Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A]WO2008075330  (GABIZON ALBERTO A [IL]) [A] 10 * claims *;
 [XI]WO2014081906  (PTC THERAPEUTICS INC [US]) [X] 1,2,5-9,11 * 15th compound; page 188 * * page 71, line 30 - page 72, line 4 * * page 90, line 5 * * page 85, line 16 - page 89, line 12 * * page 92, line 17 - line 21 * [I] 3,4,10;
 [E]WO2020185648  (PTC THERAPEUTICS INC [US]) [E] 1,2,5-9,11 * paragraph [0116] * * claim 1 * * paragraph [0136] * * paragraph [0140] * * paragraph [0105] * * paragraph [0106] - paragraph [0108] *;
 [A]  - Grenader Tal ET AL, "Long-term response to pegylated liposomal doxorubicin in patients with metastatic soft tissue sarcomas", (20090131), pages 1 - 1, URL: http://www.ncbi.nlm.nih.gov/pubmed/19342997, (20221108), XP055978813 [A] 10 * the whole document *
 [T]  - JERNIGAN FINITH ET AL, "Preclinical and Early Clinical Development of PTC596, a Novel Small-Molecule Tubulin-Binding Agent", MOLECULAR CANCER THERAPEUTICS, US, vol. 20, no. 10, doi:10.1158/1535-7163.MCT-20-0774, ISSN 1535-7163, (20210726), pages 1846 - 1857, URL: https://aacrjournals.org/mct/article-pdf/20/10/1846/3198620/1846.pdf, XP055978456 [T] 1-11 * the whole document *

DOI:   http://dx.doi.org/10.1158/1535-7163.MCT-20-0774
 [T]  - Andrew Brian ET AL, "A phase 1b study of unesbulin (PTC596) plus dacarbazine for the treatment of patients with locally recurrent, unresectable, or metastatic relapsed/refractory leiomyosarcoma", (20220601), URL: https://aacrjournals.org/cancerres/article/79/13_Supplement/292/542743/Abstract-292-PTC596-combination-therapy-for, (20221107), XP055978417 [T] 1-11 * the whole document *
 [T]  - WEETALL MARLA ET AL, "Abstract 292: PTC596 combination therapy for sarcoma", CANCER RESEARCH, 2019 San Antonio Breast Cancer Symposium, San Antonio, Texas, (20190701), vol. 79, no. 13_Supplement, doi:10.1158/1538-7445.AM2019-292, ISSN 0008-5472, pages 292 - 292, XP055978806 [T] 1-11 * the whole document *

DOI:   http://dx.doi.org/10.1158/1538-7445.AM2019-292
International search[A]US3978055  (FAURAN CLAUDE P, et al) [A] 1-11* entire document *;
 [A]WO0247690  (CYTOVIA INC [US]) [A] 1-11 * entire document *;
 [X]US2015315182  (LEE CHANG-SUN [US], et al) [X] 1-11 * entire document especially para [0001]; [0011];[0251]; [0110]; [0264] *;
 [PX]US2020024260  (LEE CHANG-SUN [US], et al) [P] 1-11 * entire document especially abstract; para [0001]; [0005]; [0109] * [X] ;
 [PX]WO2020055544  (PTC THERAPEUTICS INC [US], et al) [P] 1-11 * entire document especially claims 1-5 * [X]
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.